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Abstract  
Objective: Congenital myopathies are typically characterised by early onset hypotonia, weakness 
and hallmark features on biopsy. Despite the rapid pace of gene discovery, approximately 50% of 
patients with a congenital myopathy remain without a genetic diagnosis following screening of 
known disease genes.  
Methods: We performed exome sequencing on two consanguineous probands diagnosed with a 
congenital myopathy and muscle biopsy showing selective atrophy/hypotrophy or absence of type II 
myofibres.  
Results: We identified variants in the gene (MYL1) encoding the skeletal muscle fast-twitch specific 
myosin essential light chain in both probands. A homozygous essential splice acceptor variant (c.479-
2A>G, predicted to result in skipping of exon 5 was identified in Proband 1, and a homozygous 
missense substitution (c.488T>G, p.(Met163Arg)) was identified in Proband 2. Protein modeling of 
the p.(Met163Arg) substitution predicted it might impede intermolecular interactions that facilitate 
binding to the IQ domain of myosin heavy chain, thus likely impacting on the structure and 
functioning of the myosin motor. MYL1 was markedly reduced in skeletal muscle from both 
probands, suggesting that the missense substitution likely results in an unstable protein. Knock down 
of myl1 in zebrafish resulted in abnormal morphology, disrupted muscle structure and impaired touch-
evoked escape responses, thus confirming that skeletal muscle fast-twitch specific myosin essential 
light chain is critical for myofibre development and function.  
Interpretation: Our data implicate MYL1 as a crucial protein for adequate skeletal muscle function 
and that MYL1 deficiency is associated with a severe congenital myopathy. 
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Introduction 
Congenital myopathies are a clinically and genetically heterogeneous group of disorders 
characterised by muscle dysfunction, typically hypotonia and muscle weakness that are present at 
birth(1). Some forms can present with decreased intrauterine movements(2). Congenital myopathies 
are increasingly considered a spectrum of diseases, however they are usually sub-classified by the 
presence of distinct histopathological features on muscle biopsy which include: cores or core-like 
regions, internal nuclei, nemaline bodies and/or fibre-type disproportion. Mutations in over 20 genes 
are now known to cause congenital myopathies(1, 3, 4). Typically, congenital fibre type disproportion 
(CFTD) describes the pathological feature of a myopathy in which the type I myofibres are smaller 
than type II myofibres by 25%, in the absence of other pathological features (OMIM 255310). 
Mutations of five different genes (ACTA1, MYH7, RYR1, SEPN1 and TPM3) have been associated 
with CFTD; all of which are also associated with various structural features(5-9). Congenital 
myopathies characterised by a relative loss or hypotrophy of type II myofibres are much less frequent. 
Dominant and recessive mutations of MYH2 (OMIM 160740), encoding myosin heavy chain type 
IIA, cause proximal myopathy, external ophthalmoplegia and loss or hypotrophy of type IIA 
myofibres (OMIM 605637)(10, 11). Recently, bi-allelic mutation of TNNT3, encoding the skeletal 
muscle troponin-Tfast was identified in a patient presenting with arthrogryposis, nemaline myopathy 
and marked atrophy of type II myofibres(12). Small type II myofibres are also a non-specific feature 
in congenital myasthenic syndromes(13), in ageing of muscle, critical illness myopathy and following 
steroid therapy, where histochemical IIB myofibres are affected(14). Here we present two isolated 
cases presenting with a severe congenital myopathy with absent or very small type II myofibres and 
bi-allelic mutations in the gene (MYL1; OMIM 160780) encoding the skeletal muscle fast-twitch 
specific myosin essential light chain.  
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Results 
Clinical features and muscle pathology 
The proband in Family 1 (Turkish origin) was the first child of second-degree consanguineous parents. 
There was no family history of neuromuscular disease. The pregnancy was complicated by 
polyhydramnios, with normal fetal movements. The boy was delivered at 36 weeks gestation by 
Caesarean section; he was floppy with no respiratory efforts and required ventilation via endotracheal 
tube.  
 
Examination in the neonatal period demonstrated mild facial weakness, normal eye movements and 
no ptosis, a thin muscle build with severe weakness affecting axial and proximal muscles of both the 
upper, and to a lesser extent, lower limbs. He required nasogastric tube feeding. He had normal 
cardiac examination, ECG and echocardiogram. 
 
Deep tendon reflexes were absent, and there were mild flexion contractures in the elbows, knees and 
hips. EMG was myopathic and repetitive nerve stimulation showed a decrement at 3 Hz, increased 
after tetanic stimulation. Creatine kinase levels and brain MRI were normal. In view of the differential 
diagnosis between a congenital myopathy and a congenital myasthenic syndrome, he was empirically 
started on pyridostigmine. 
 
In the first few months of life some partial antigravity movements in the upper and lower limbs 
appeared. At the age of 3 months he was extubated into CPAP but after a few weeks he required re-
intubation, and gastrostomy with Nissen’s fundoplication. A stimulated single fibre EMG at 5 months 
showed minimal increased jitter not affected by the administration of tensilon, interpreted as a non-
specific finding in the context of a myopathy. The pyridostigmine was therefore stopped, with no 
change in clinical status. The patient eventually died of respiratory failure at the age of 7 months. 
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Haematoxylin and eosin stained sections of the muscle biopsy (Figure 1A) showed marked myopathic 
features, with severe fatty infiltration and diffuse perimysial and endomysial fibrosis. There was 
marked variation in myofibre size (<5-80 μm; normal range for age: 15-20 μm). There was a 
distinctive pattern of ‘florets’ of small slightly granular basophilic myofibres surrounding larger 
myofibres resembling a flower with a central area surrounded by petals. The small myofibres 
expressed fast (Figure 1B) and fetal myosin and some also expressed developmental myosin and 
cardiac actin, whilst the hypertrophic myofibres expressed only slow myosin (Figure 1C). 
Nicotinamide adenine dinucleotide tetrazolium reductase (NADH-TR) staining (Figure 1D) was 
indistinct but uniform staining of larger myofibres and a mixed pattern of dark and light smaller 
myofibres was just apparent. Endomysial connective tissue was increased but there were very few 
internal nuclei. Gomori trichrome staining showed some focal circular red stained areas that were not 
reducing bodies (negative for menadione-linked glycerophosphate dehydrogenase without substrate) 
but may have been cytoplasmic bodies. There was no apparent necrosis, although acid phosphatase 
activity was elevated. Immunolabelling of sarcolemmal proteins was normal. In addition to fast and 
fetal myosin, the small myofibres also expressed high levels of cardiac α-actin, desmin and NCAM, 
suggesting immaturity and/or non-innervation.  
 
Family 2 is Turkish; the parents are second cousins. There is no family history. The female proband 
was born at 37 weeks gestation by Caesarean section with a birth weight of 2,400g. Intrauterine 
movements were reduced. She was mechanically ventilated for the first 37 days of life; dependent on 
ventilatory support at the age of 3 months when she presented with sudden apnea. When evaluated at 
the age of 8 months (Supplementary Video 1); she was an alert baby with a myopathic face, high-
arched palate, facial weakness, normal conjugated eye movements, hypotonia and generalised 
weakness with some effort to move using mainly proximal muscles, and head lag. There was 
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markedly increased respiratory effort with lower costal recession, poor abdominal wall movements, 
asynchrony between the respiratory effort and mechanical ventilation. Serum creatine kinase level 
was normal. Cardiac examination (ECG and echocardiogram) was normal. Differential diagnosis 
included congenital myopathies.  
 
At the age of 18 months the patient developed respiratory arrest due to a tracheostomy cannula 
obstruction and stayed in the hospital for 6 weeks. She gradually acquired head control and the ability 
to sit with support at ~18 months of age, sit unaided at 24 months of age and walk with support at 3 
years of age. 
 
She is hypotonic with marked axial weakness, especially involving the neck flexors, and requires 
night-time ventilation without swallowing and feeding difficulties.  
 
Muscle biopsy revealed non-specific myopathic features with mild to moderate variation in myofibre 
size, randomly scattered small myofibres and rare myofibres undergoing degeneration. A mild 
increase in endomysial and perimysial fibrous tissue was present (Figure 1E). The typical 
checkerboard pattern of fibre types was not observed with staining for oxidative enzymes (NADH-
TR, succinate dehydrogenase [SDH], cytochrome C oxidase [COX; Figure 1F]). ATPase stain (pH 
9.5) revealed pronounced predominance of type I myofibres, with only a few small type II myofibres 
(Figure 1G). No sample for electron microscopy was available. 
 
Identification of mutations in MYL1 
Exome sequencing of DNA from the proband of Family 1, identified a homozygous essential splice 
acceptor variant (intron 4; c.479-2A>G) in the gene encoding myosin, light chain 1, alkali, skeletal, 
fast (MYL1, OMIM 160780), also known as the fast skeletal muscle-specific essential light chain 
(ELC). Evaluation in Alamut revealed that this variant is likely to result in the formation of an 
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acceptor site 2 bps downstream (NNSPLICE, MaxEntScan and Human Splice Finder) and in-
frame skipping of exon 5. This likely removes 13% of the protein sequence, including the end of the 
second EF-hand motif, a region conserved to Baker’s yeast (Alamut). Muscle was not available for 
cDNA analysis. Bi-directional Sanger sequencing confirmed this variant and showed that as expected, 
each parent was a carrier. This variant is novel and has not previously been found in any control 
databases (1000genomes, ExAC/GnomAD browsers).  
 
NSES gene panel analysis of Proband 2 identified no mutations. The exome data showed 816 filtered, 
rare, coding variants. Overlaying these with the FANTOM5 52 highly enriched candidate muscle 
disease genes, identified a homozygous missense variant (c.488T>G) in exon 5 of MYL1 
(Supplemental Figure 1A) as the most likely candidate. Skeletal muscle enrichment of MYL1 within 
FANTOM5(15) and GTEx(16) is shown in Figure 2A. Sanger sequencing confirmed the variant and 
showed each parent was a carrier (Supplemental Figure 1B). The variant occurs within the same EF-
hand domain that is likely deleted in Proband 1. It results in substitution of a highly-conserved amino-
acid residue (p.(Met163Arg)) Figure 2B). This variant is novel and not in any control databases 
(1000genomes, ExAC/GnomAD browsers). The substitution is suggested to be disease causing by all 
in-silico predictors (MutationTaster, SIFT [damaging, 0.000], PolyPhen-2 [probably damaging, 
0.997], Provean [deleterious, -5.333], MutationAssessor [FI score 3.925]).  In addition, the variant 
occurs 10 bp from the intron/exon boundary and is suggested to affect splicing (MutationTaster) and 
to introduce a SF2 binding site (Alamut). However, patient muscle was unavailable for cDNA studies. 
 
No known or likely pathogenic variants were identified in any known neuromuscular disease genes 
in the exome data for either proband. 
 
MYL1 protein studies 
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An antibody raised against full-length human MYL1 gave a single band at ~21 kDa in mouse skeletal 
muscle (diaphragm, EDL, quadriceps and soleus) but not the heart or brain (Figure 2C). This band 
corresponds to the full-length MLC1F isoform. No band corresponding to the truncated MLC3F 
isoform was observed. Analysis of MYL1 by immunoblotting of the muscle biopsies from the 
probands revealed an apparent total loss of MYL1 relative to fetal and adult human healthy control 
muscles (Figure 2D-E).  
 
MYL1 protein modeling 
MYL1 encodes the fast myofibre non-regulatory myosin alkali/essential light chain (ELC) isoforms 
MLC1F and MLC3F, with the N-terminus truncated MLC3 isoform being 44 residues shorter than 
MLC1. Two ELCs, two myosin phosphorylatable, or regulatory, light chains (RLCs) and two myosin 
heavy chains make up each myosin multi-protein complex unit. Both ELCs and RLCs bind to the 
lever arm neck of the myosin cross-bridge/head, to the first two IQ motifs, which are 22-25 amino 
acid regions characterised by the conserved consensus sequence IQxxxRGxxxR. Although, from a 
structural point of view, the myosin ELC belong to the EF-superfamily of Ca2+-binding proteins, they 
have lost the possibility to bind Ca2+ throughout evolution(17, 18). Nevertheless, the ELC still 
displays the helix-loop-helix fold typical of EF-hand domains, which is presented four times in the 
mature protein, which is formed by 194 amino acids (MLC1F; MLC3F). Despite their lost ability of 
actively acting as Ca2+-controlled regulators, myosin ELCs are still central to the proper functioning 
of myosin. The ELC plays an important role in regulating both cardiac and skeletal muscle 
contraction: it stabilises the neck lever arm structure to produce steps of a definite size(19), and also 
play a role in fine-tuning of the molecular motor(20). 
 
MLC1F and MLC3F, have discrete promoters within MYL1 and result from alternative splicing. To 
date, no high-resolution structure of human MLC1F or MLC3F is available. Nevertheless, ELC 
structures, invariably in their bound conformation to MHC, have been obtained for other organisms 
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(e.g. chicken, scallop and yeast). Due to the extremely high degrees of sequence identity, these can 
be used as templates to safely predict the three-dimensional structure of their Homo sapiens 
counterparts by homology modeling. Using the PDB structure 2W4A as template, we built a model 
for MLC3F bound to its target site on the MHC, the first IQ motif of myosin II. 
 
In the model, p.Met163 is in close contact with p.Leu802 and p.Cys798 of the myosin IQ domain 
suggesting it may be involved in a hydrophobic interaction with the leucine side chain, playing a role 
in IQ recognition and binding (Figure 3A). Such an interaction would be lost upon substitution to an 
Arg, likely impacting the ELC interaction with MHC. Although the p.Met163 hydrophobic 
interaction with p.Leu802 on MHC could facilitate the binding of the essential light chain to the heavy 
chain, electrostatic interactions may play a major role. IQ domains have been reported to rely on 
electrostatics for acquiring the proper orientation and/or for correct binding to partners. The modeled 
IQ portion of MHC has a high density of surface-exposed arginine side chains and therefore a dense 
region of positive electrostatic potential, especially in the portion which is thought to interact directly 
with MLC3. The ELC exposes a wide region of negative electrostatic potential (Figure 3B). 
Electrostatic interactions therefore likely play a crucial role in the binding of ELC to MHC. p.Met163 
is located on the edge of the negative potential groove. Substitution to Arg should introduce repulsion 
towards the positive potential region of IQ, affecting the correct binding of the C-terminal lobe of 
ELC and its stabilisation of the heavy chain structure and thus impacting the proper structure and 
functioning of the myosin motor. 
 
Morpholino knockdown of myl1 in zebrafish demonstrates the essential role of myl1 for muscle 
development and function 
To study the impact of myl1 loss-of-function during muscle development, we generated morpholino 
(MO) knockdown myl1 zebrafish models. We used two MOs, one targeting the myl1 AUG start codon 
(MO AUG) and the other targeting the splice site of exon 2 (MO Spl), thus creating two independent 
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myl1 MO zebrafish models. In un-injected control embryos, a band corresponding to normal splicing 
of myl1 exon1-exon4 (440 bp) was present while no band was detected when the primer pair in exon1-
intron1 was used (Figure 4E). RT-PCR analysis of the MO Spl morphants demonstrated the normal 
exon1-exon4 band and an additional larger band (449 bp) due to the retention of intron 1. Sanger 
sequencing of the intronic inclusion revealed an in-frame stop codon at intronic position 42. The 
results demonstrate that the MO Spl is targeting the exon 2 splice site and is causing aberrant myl1 
splicing.  
 
Consistent phenotypes were observed between the myl1 MO AUG and MO Spl morphants. At 48 hpf, 
the morphants had curved bodies, bent tails (Figure 4A) and a marked reduction in touch-evoked 
escape response (Supplementary Videos 1, 2, 3). Muscle structure measured by the birefringence 
assay resulted in a bright signal indicating highly-organised myofibres in the un-injected controls 
(Fig. 4 Bi), whereas in the myl1 morphants a significant reduction in birefringence demonstrated gross 
impairment of the skeletal muscle structure (Figure 4Bii, iii). Phalloidin labeling in the un-injected 
control embryos revealed densely packed and organised myofibres (Figure 4Ci, iv). In the myl1 
morphants, the myofibres appeared “wavy”, sparse and disordered (Figure 4Cii, iii, v, vi). Taken 
together, these data indicate that myl1 is required for the normal formation of myofibres and/or 
myofibre maintenance and thus appropriate muscle function. 
 
To evaluate the effect of the c.488T>G MYL1 variant, we attempted a complementation assay but the 
injected mRNA exacerbated the phenotype (data not shown). We then injected human WT or 
c.488T>G MYL1 mRNA in wild-type zebrafish embryos and the resulting phenotype was compared 
to un-injected control fish (UIC). At 48 hpf, in WT mRNA injected zebrafish, 50% of the embryos 
showed a mild phenotype, 14% were moderately affected and 36 % of the fish showed a severely 
affected phenotype (Supplementary Figure 2). In zebrafish injected with c.488T>G MYL1 mRNA all 
embryos demonstrated a mild phenotype (Supplementary Figure 2). Thus, while overexpression of 
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WT MYL1 mRNA induced an aberrant phenotype in the injected zebrafish, the lack of a severe 
phenotype in the c.488T>G MYL1 mRNA injected fish demonstrates that the mutant mRNA is 
relatively non-functional and supports the pathogenicity of the c.488T>G MYL1 variant.  
 
Discussion  
Here we describe the identification of recessive mutations in MYL1 in two unrelated Turkish 
individuals with severe congenital myopathy and selective involvement of type II myofibres: small 
type II myofibres in Proband 1 and almost absence of type II myofibres in Proband 2. These features 
are highly unusual: small type I myofibres are typical in congenital myopathies, whilst small type II 
fibres are very rarely seen. It was not possible to determine if the type II/fast myofibres were atrophic 
or hypotrophic, or if they failed to develop. In Proband 1 myosin isoforms associated with immaturity 
were co-expressed with fast myosin; co-expression of immature proteins can occur in both atrophic 
and hypotrophic myofibres. In addition, some of the very small fast myofibres expressed cardiac actin 
suggesting that they were immature. Electron microscopy to look for redundant basal lamina 
associated with atrophy was not possible due to lack of tissue.  
 
The MYL1 gene encodes two splice isoforms of skeletal muscle fast essential light chain (designated 
MLC1F and MLC3F) (OMIM 160780)(21), which are well studied in model organisms. They interact 
with fast myosin heavy chain (MHC) as either homodimers or heterodimers.  
 
It has long been known that the “essential” myosin light chains are necessary for the proper 
contraction of muscle. Removal of the essential light chain from chicken pectoralis myosin reduced 
the velocity of actin filament sliding to around a sixth of normal speed(22). Another study showed 
that selective removal of myosin ELCs from chicken skeletal myosin resulted in ~50% reduction in 
isometric force, whereas removal of the regulatory light chains (RLC) had no effect(23).   
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There are several isoforms of myosin ELCs and RLCs, each encoded by a different gene. MYL2 
encodes the cardiac and slow-twitch muscle fibre specific regulatory myosin light chain (OMIM 
160781), MYL3 the ventricular and slow-twitch skeletal myofibre essential light chain, MYL4  an 
essential light chain isoform present in embryonic cardiac muscle and adult atria (OMIM 160770) 
and MYL6 a smooth-muscle and non-muscle specific regulatory light chain (OMIM 609931).  Human 
genetic diseases have previously been associated with MYL2, MYL3 and MYL4.  
 
Dominant mutations of MYL2 (the cardiac and slow-twitch specific regulatory light chain, OMIM 
160781) and MYL3 (OMIM 160790) cause hypertrophic cardiomyopathy. Recessive mutations in 
MYL2 cause cardiomyopathy in combination with a type I fibre myopathy(24). Affected individuals 
had normal prenatal and perinatal periods, but developed rapidly progressive muscle weakness from 
a few weeks of age and all died through heart failure by 6 months. Skeletal muscle from affected 
individuals showed increased variation in myofibre size with small type I myofibres and reduced 
abundance of MYL2(24). Dominant mutations in MYL2 are missense mutations, whereas recessive 
MYL2 mutations are null mutations, including splice-site and frameshift mutations. Both 
dominant(25) and recessive(26) missense mutations in MYL3 cause cardiomyopathy. Missense 
mutation of MYL4 causes dominant atrial fibrillation(27), homozygosity for a frameshift mutation 
causes recessive atrial fibrillation(28).  
 
Myl1 is an early marker of differentiating fast muscle in zebrafish(29). By in situ hybridisation, myl1 
was detected in developing embryos from the 8-somite stage onwards, whereas other markers of fast-
twitch muscle were only observed from the 10-somite stage. Myl1 transcript levels declined with 
development in post-somitogenic stages. In fish knocked-down for both myf5 and myod by 
morpholino injection, myl1 was reduced or absent, suggesting that myl1 expression is downstream of 
myf5/myod.  Zammit et al. showed that in mice, the Mlc1f promoter was active in embryonic, fetal 
and adult fast-twitch skeletal muscle, whereas the Mlc3f promoter was up-regulated during fetal 
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development and remained active in adult fast-twitch skeletal muscle(30). Normal development of 
myotubes and myofibrillogenesis is impaired in chicken myoblast/myotube cultures by reduction of 
MLC1F, mediated by antisense knock down(31). This may relate to the atrophy/hypotrophy of type 
II myofibres seen on patient biopsy.  
 
There was a marked reduction in type II myofibres in muscle biopsies from both probands. The 
muscle biopsy from Proband 1 was striking in having a ‘floret’ appearance of small fast myofibres 
surrounding slow myofibres.  The larger type I fibres were, from the patient phenotype, insufficient 
to maintain muscle function. Stuart et al. recently studied the MHC and MLC composition of 
individual human skeletal myofibres by laser-capture micro-dissection followed by immunoblotting 
using the MYL1 antibody (SAB1409338) and mass spectrometry. Their data suggested MYL1 was 
not restricted to fast myofibres, but was in fact the most abundant MLC species in all myofibres (I, 
IIA, IIX), though with higher abundance in type IIA/IIX compared with type I myofibres(32). Thus, 
while MYL1 is considered the skeletal muscle fast-specific ELC, it may be critical to the function of 
all skeletal myofibre types. That type I fibres were not small may result from the presence of slow 
twitch essential light chain MYL3.  
 
The severe atrophy/hypotrophy of type II myofibres also raised the possibility of a congenital 
myasthenic syndrome (CMS). This was initially considered because of a modest electrodecrement on 
repetitive nerve stimulation and a borderline jitter in the proband from Family 1. However, modest 
secondary abnormalities of the neuromuscular junction are well known to occur in certain congenital 
myopathies(3), and this patient did not appear to benefit from pyridostigmine therapy. In addition, 
involvement of CMS genes was ruled out by the analysis of the relevant genes. 
 
By western blotting, we showed absence of MYL1 protein from the muscle biopsies of both patients. 
The protein modeling suggested that the p.(Met163Arg) substitution could alter binding of MYL1 to 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddy320/5095322 by St G
eorge's U
niversity of London user on 26 Septem
ber 2018
	 15	
the MHC and thereby impact myosin function. However, our western blots suggest the variant results 
in reduced stability of the mutant MYL1. 
 
The patients had profound muscle weakness. This suggests that MYL1 is critical for muscle function 
or that compensation by other essential light chains is not able to replace the function of MYL1, 
indicating a lack of redundancy between essential light chain isoforms. Relevant to this, no 
compensatory upregulation of other essential light chains was seen by Nawrotzki et al. following 
experimental knock down of MLC1f(31). In this study we demonstrated that knock down of myl1 in 
zebrafish led to aberrant muscle development evidenced by the curved body, significantly reduced 
motility and gross impairment of myofibre organisation; supporting the crucial role of myl1 for 
muscle development and function. Over-expression of the c.488T>G MYL1 variant in wild-type 
zebrafish embryos only produced a mild phenotype. Over-expression of other skeletal muscle 
proteins are known to be deleterious(33, 34). Whereas over-expression of WT MYL1 produced a 
moderate to severe phenotype in 50% of fish. This assay suggests that the c.448T>G variant is 
relatively non-functional and confirms the pathogenicity of this substitution.  
 
Identification of the MYL1 mutation in Family 2 was aided by a gene prioritisation approach based 
on gene enrichment and abundance within the FANTOM5 datasets. This represents a novel approach 
to identify candidate genes. New approaches are much needed, in order to improve the rate of accurate 
gene discovery in small families or isolated probands with rare monogenetic diseases(4). Interestingly, 
Neto et al. through data mining to highlight candidate genes for monogenic myopathies, had 
previously identified MYL1 as a top candidate for a range of muscle diseases, including congenital 
myopathies(35). 
 
Here we present comprehensive evidence that bi-allelic loss-of-function MYL1 mutations represent a 
novel, albeit rare, cause of severe congenital myopathy. The unusual muscle pathology of type II 
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myofibre absence or hypotrophy appears the most characteristic feature of MYL1 myopathy. Patients 
with a congenital myopathy and small or absent type II myofibres should be screened for mutations 
in MYL1. 
 
Materials and methods  
Ethics approvals 
All individuals were enrolled under appropriate procedures in accordance with the ethical standards 
of the responsible committees on human experimentation (UWA Human Research Ethics Committee 
RA/4/1/4403 and Great Ormond Street Hospital Research Ethics Committees GOSH 00/5802). 
 
Exome sequencing  
Family 1 
Exome sequencing was performed on the proband of Family 1 within the UK10K project. Sequencing, 
alignment and variant calling were as previously(36).  
 
Family 2 
DNA extracted from peripheral blood of the proband from Family 2, was sequenced using version 1 
of the Neurogenetic Sub-Exomic Sequencing (NSES) gene panel, as previously described(37), 93.7% 
of the targeted 336 genes were covered to >20-fold. Exome sequencing was performed using the Ion 
Torrent platform and data was mapped, annotated and filtered as previously(38). Average coverage 
was 128-fold with 90.7% of the exome covered to >20-fold.  
 
Using the FANTOM5 (functional annotation of the mammalian genome) promoter level expression 
atlas(15) we generated a ranked list of skeletal muscle enriched genes. Source file with precomputed 
relative expression was downloaded from: 
http://fantom.gsc.riken.jp/5/tet/data/hg19.cage_peak_phase1and2combined_rel_expr.txt.gz. For 
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each gene, we identified the promoter with the most enriched expression in skeletal muscle samples 
compared to median across the entire FANTOM5 collection [log10(max expression in any skeletal 
muscle sample + 1) – log10(median expression in the FANTOM5 collection + 1)]. The 76 skeletal 
muscle sample tissue and primary cell expression profiles used are listed in Supplementary Table 1. 
This identified 83 annotated protein-coding genes with a promoter showing more than 1,000-fold 
enriched expression in skeletal muscle (Supplementary Table 2). Of these, 31 had already been 
associated with human genetic muscle disease. The remaining 52 were prioritised as candidate 
myopathy genes. Many of these highly enriched genes are known striated muscle genes but many are 
not, thus this approach does not rely on a priori knowledge of gene function for prioritisation.  
 
Histological analysis 
An open muscle biopsy, from each proband, was frozen in isopentane cooled in liquid nitrogen, 
stained and immunolabelled according to standard procedures(14).  The amount of muscle obtained 
from both cases was too small for electron microscopy to be performed. The biopsy from Proband 1 
was taken from the quadriceps muscle at 5 months of age.  A biopsy of the vastus lateralis was 
obtained from Proband 2 at 8 months of age. 
 
Western blotting 
Skeletal muscle from Proband 1 and a control was homogenised manually in lysis buffer containing 
75mM Tris-HCl (pH 6.8), 1% SDS and protease inhibitor. Protein concentration was assessed using 
BCA assay. 40 μg of protein was loaded on NuPAGE 4–12% Bis-Tris protein gels, separated by 
electrophoresis for 1.5 hours and then transferred to nitrocellulose membrane for 1.5 hours. The 
membrane was blocked in Odyssey blocking buffer for 1 hour at room temperature followed by 
incubation with primary antibodies against MYL1 (Sigma-Aldrich, SAB1409338) and β-Actin (Cell 
Signalling, 4967) overnight at 4 °C. The membrane was washed 3 times for 10 minutes with 0.1 M 
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PBS and incubated with IRDye® 800CW Donkey anti-Mouse IgG and IRDye® 680RD Donkey anti-
Rabbit IgG for 1 hour at room temperature. Following three washes for 10 minutes in 0.1 M PBS, the 
blot was imaged using an Odyssey Infrared Imaging System. 
 
Muscle lysates for Proband 2, human controls (healthy human adult excess tissue from in vitro 
contracture testing and from a 23/40 gestation fetus) and mouse tissues were prepared as outlined 
below. Cryostat cut sections were lysed in Laemmli lysis buffer supplemented with protease inhibitor 
and DTT, boiled for 5 minutes at 94 °C, centrifuged and the supernatant retained.  The total protein 
was quantified using a PierceTM BCA Protein quantification kit.  NuPAGETM Bis-Tris 4-12% gradient 
gels were loaded with 10 μg of protein and run at 150 V for 1 hour. Gels were transferred onto PVDF, 
blocked for 1 hour at room temperature in blocking solution and then incubated with primary 
antibodies overnight. Membranes were rinsed three times and then incubated with HRP-conjugated 
secondary antibodies. Membranes were rinsed again and detection was performed using Pierce ECL 
Plus Western Blotting Substrate. Primary antibodies: MYL1 (SAB1409338; 1:2,000); sarcomeric 
actin (clone 5C5; 1:200,000) and GAPDH (clone GAPDH-71.1; 1:40,000). The Coomassie stained 
MHC band was also used to demonstrate approximate loading between muscle samples.  
 
Protein modeling 
The model of myosin essential light chain 3 (MLC3) in complex with myosin heavy chain (MHC), 
was built by homology modeling using MODELLER 9.16(39). We used as template the structure of 
the MLC3-MHC complex from Gallus Gallus (PDB entry 2W4A)(40) that displays a high degree of 
sequence identity (more than 80%) with the human MLC3 and myosin II. The models obtained were 
evaluated by DOPE score(41) and VADAR web server(42). The electrostatic properties were 
investigated using the APBS software. The pqr input file required to run APBS was prepared using 
PDB2PQR(43). The electrostatic potential was obtained by solving the linearised Poisson–Boltzmann 
equation (LPBE) at 298.5 K, using dielectric constant values of 2 and 78.54 for protein (solute) and 
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solvent, respectively.  
 
myl1 zebrafish analysis 
Antisense morpholino oligonucleotides (MO) (Gene Tools, LLC) were designed against the myl1 
start codon (TCTTAGCGTCCTTCTTAGGTGCCAT) and against the myl1 intron1-exon2 splice site 
(TCGAGCTGCAGGAAAACAGAGTTAT). Knockdown of myl1 was achieved by MO injections at 
doses of 1 ng for the MO against the start codon (MO AUG) and at 3 ng for the MO against the 
intron1-exon2 splice site (MO Spl). MOs were injected into zebrafish embryos at the 1–2 cell stage. 
The injected embryos were incubated at 28.5°C and dechorionated at 24 hours post fertilisation (hpf).  
 
Embryos at 48 hpf were mounted in 3% methylcellulose and the structure of the zebrafish muscle 
assessed using birefringence microscopy. 
 
Immunofluorescent phalloidin (Molecular Probes) staining was performed on whole mounted 
zebrafish at 48 hpf. Confocal microscopy imaging was performed using a Leica confocal microscope 
and images were analysed using ImageJ software. 
 
The specificity of the MO Spl was confirmed using RNA extracted from morphant and control 
zebrafish (n=20 in each group) at 48 hpf. cDNA was synthetised using High Capacity RNA-to-
cDNA™ Kit (Thermo Fisher Scientific).  
 
Clones containing human wild-type (WT) MYL1 or c.488T>G MYL1 variant were purchased from 
GenScript ®. The clones were grown in NEB® 10-beta Competent E. coli cells and DNA was 
extracted using EndoFree Plasmid Kit (Qiagen). Linearisation of the plasmids was done by digestion 
with NotI enzyme at 37 °C for 2 hours. Capped WT and c.488T>G MYL1 mRNA was generated 
using the mMessage mMachine SP6 Transcription kit (Thermo Fisher Scientific). 100 pg of WT or 
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c.488T>G MYL1 mRNA were injected into 1-cell stage zebrafish embryos. 
 
Resources 
1000genomes:http://www.1000genomes.org 
ExAC:http://exac.broadinstitute.org 
Exome variant server:http://evs.gs.washington.edu 
FANTOM5:http://fantom.gsc.riken.jp/5/ 
gnomADbrower: http://gnomad.broadinstitute.org  
Mutation Assessor: http://mutationtaster.org 
MutationTaster: http://mutationtaster.org 
OMIM:http://omim.org 
PolyPhen-2: http://genetics.bwh.harvard.edu/pph2/ 
Provean: http://provean.jcvi.org/index.php 
SIFT: http://sift.jcvi.org 
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Figure legends 
Figure 1: Pathological features of MYL1-myopathy. 
Staining of the skeletal muscle biopsy taken from the proband of Family 1 aged 5 months: 
haematoxylin and eosin (A), pan fast myosin heavy chain (B) and slow myosin heavy chain (C)  
showing many small myofibres with fast myosin surrounding larger myofibres with slow myosin and 
NADH-TR (D) showing indistinct fibre typing but uniform larger myofibres and some darker smaller 
myofibres; and muscle biopsy from the proband of Family 2 aged 8 months: haematoxylin and eosin 
(E) COX showing indistinct fibre typing (F), and ATPase pH 9.5 showing almost uniform type 1 
myofibres (G). Scale bars represent 100 μm (A-D) or 50 μm (E-G). 
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Figure 2: MYL1 expression and protein abundance. 
(A) Expression of MYL1 in skeletal muscle samples compared to other samples from FANTOM5 
(tissue and primary cell) and GTEx databases. Units of expression are TPM (tags per million) for 
FANTOM5 and RPKM (reads per kilobase per million mapped reads) for GTEx. Number of samples 
in each comparison for FANTOM5 (skeletal muscle = 76, other = 1,753), GTEx (skeletal muscle = 
430, other = 8,125). (B) Evolutionary conservation of p.Met163. (C) Western blotting of lysates of 
mouse tissues (pooled from three 8-week old C57BL6 mice) revealed that MYL1 (antibody 
SAB1409338) was similarly abundant in mouse skeletal muscles (diaphragm, EDL, quadriceps and 
soleus). Loading: quadriceps (1), EDL (2), soleus (3), diaphragm (4), heart (5), brain (6). Western 
blotting for GAPDH and Coomassie staining of the myosin heavy chain (MHC) band are shown to 
demonstrate similar total protein loading. (D) Western blotting for MYL1 (green) and β-actin for 
control muscle and muscle from the proband (P1) of Family 1. (E) Western blotting of the muscle 
biopsy from the proband (P2) of Family 2, compared with human fetal (23/40 weeks gestation) and 
adult skeletal muscle (C1, C2) showed a relative loss of MYL1. Coomassie staining of the MHC band 
and western blotting for sarcomeric actin (5C5 antibody) are shown to demonstrate similar loading 
of sarcomeric proteins between samples.  
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Figure 3: Protein modeling of the p.(Met163Arg) substitution. 
(A) Cartoon and surface representations of the modeled structure of MLC3 (cyan) bound to the IQ 
motif of the myosin heavy chain MHC (orange and green, to distinguish between regions contacting 
or not the MLC3, respectively). Met163 on MLC3 is represented as sticks and colored in cyan; 
Leu802, located on the IQ domain and interacting with Met163, is colored in orange. (B) Left: 
Electrostatic potential calculated separately for MLC3 and for the IQ motif of MHC and mapped on 
their molecular surfaces. Potentials less than -5 kT/e are colored in red, and those greater than +5 
kT/e are depicted in blue. The position of Met163 is indicated by a yellow star. Right: same as in left, 
but with the IQ motif represented as a cartoon and shown in the position it occupies when interacting 
with MLC3. 
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Figure 4: Knockdown of myl1 in zebrafish causes abnormal muscle development assessed at 48 
hpf.  
(A) General morphology of uninjected control embryos (i), embryos injected with 1 ng of the MO 
targeting the myl1 AUG start codon (ii) and embryos injected with 3 ng of the myl1 splice blocking 
MO (iii). Scale bar represents 400 μm. (B) Birefringence of uninjected control embryos (i) and myl1 
morphant embryos (ii, iii). Scale bar represents 200 μm. (C) Phalloidin staining of F-actin (red) of 
myl1 morphant embryos (ii, iii at 20x magnification; v, vi at 40x magnification) and uninjected 
control embryos (i at 20x magnification; iv at 40x magnification).  Scale bar represents 20μm (20x 
magnification) and 40μm (40x magnification). (D) Schematic representation of the myl1 splice 
blocking MO target site shown in red. Presented are the exons and introns with the corresponding 
size. Arrows present the positions of the primers used to confirm the splicing defect in the myl1 splice 
blocking morphants. (E) RT-PCR validation of the splicing defect caused by the myl1 splice blocking 
MO. The primer pair F1-R1 produced a band for the endogenous myl1 product at the expected size 
(440 bp) in the uninjected controls (UIC, lane 2) and in myl1 splice blocking MO morphants (MO 
Spl, lane 4). No product was detected using primer pair F1-R2 in the uninjected controls (UIC, lane 
3). In myl1 splice blocking MO morphants a band with the expected size of 449 bp corresponding to 
inclusion of intron 1 was detected (MO Spl, lane 5). 
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